Immunovaccine Secures $5 Million Loan to Support Clinical Stage Cancer Vaccines - - BioPharm International

ADVERTISEMENT

Immunovaccine Secures $5 Million Loan to Support Clinical Stage Cancer Vaccines



Immunovaccine Inc., a clinical stage vaccine company, has obtained a loan of $5 million from the Province of Nova Scotia, to be used to fund a portion of working capital through 2016. The secured loan is interest bearing and repayable in 2018.

Immunovaccine currently has several vaccine programs in development, including two clinical stage cancer vaccines, which have both demonstrated positive immune response and safety results in human studies. The company announced in July that it will collaborate with Canada’s NCIC Clinical Trials Group to conduct a Phase II study of its lead cancer vaccine, DPX-Survivac, in patients with advanced ovarian cancer.

Source: Immunovaccine Inc.

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Lundbeck CEO Resigns Due to Code of Conduct Breach
November 24, 2014
IMS: Global Spending on Medicines to Rise 30% by 2018
November 24, 2014
Janssen Partners with Transposagen Biopharmaceuticals for CAR-T Therapies
November 24, 2014
Amgen Opens Single-Use Manufacturing Plant in Singapore
November 20, 2014
GPhA Issues Statement on Generic Drug Costs
November 20, 2014
Author Guidelines

Click here